Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Titel:
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Auteur:
Abraham, Sonya Juel, Helene B Bang, Peter Cheeseman, Hannah M Dohn, Rebecca B Cole, Tom Kristiansen, Max P Korsholm, Karen S Lewis, David Olsen, Anja W McFarlane, Leon R Day, Suzanne Knudsen, Sara Moen, Kjersti Ruhwald, Morten Kromann, Ingrid Andersen, Peter Shattock, Robin J Follmann, Frank